Use of biomarkers in the management of children with lupus

Current Rheumatology Reports

Volumn 15, Issue 3, 2013, Pages

  Binder, Elisabeth ^a   Edelbauer, Monika ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Autoantibodies; Biomarker; Cell bound complement activation products; Complement; Juvenile onset systemic lupus erythematosus; Monocyte chemoattractant protein 1; Neutrophil gelatinase associated lipocalin; SLE nephritis; Urinary biomarkers; 1 Acid glycoprotein

Indexed keywords

AUTOANTIBODY; B7 ANTIGEN; BIOLOGICAL MARKER; CD4 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CERULOPLASMIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C9; CYTOKINE; DOUBLE STRANDED DNA ANTIBODY; INTERFERON; MONOCYTE CHEMOTACTIC PROTEIN 1; NATURAL KILLER CELL RECEPTOR NKG2D; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OROSOMUCOID; TRANSFERRIN;

ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILDHOOD DISEASE; COMPLEMENT ACTIVATION; DISEASE ACTIVITY; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; GENOMICS; GLOMERULUS FILTRATION RATE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; PATIENT MONITORING; PROTEINURIA; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

EID: 84872684474     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0312-0     Document Type: Article

References (67)

1. Midgley A, Beresford MW. Cellular localization of nuclear antigen during neutrophil apoptosis: mechanisms for autoantigen exposure? Lupus. 2011;20(6):641-6.
2. Pan Y, Sawalha AH. Epigenetic regulation and the pathogenesis of systemic lupus erythematodes. Transl Res. 2009;153(1):4-10.
3. Ahearn JM, Liu CC, Kao AH, et al. Biomarkers for systemic lupus erythematosus. Transl Res. 2012;159:326-42.
4. Cook HT, Botto M. Mechanisms of disease: the complement system and the pathogenesis of systemic lupus erythematodes. Nat Clin Prac Rheumatol. 2006;2(6):330-7.
5. Watson L, Beresford MW. Urine biomarkers in juvenile-onset SLE nephritis. Published online Pediatr Nephrol. 2012; doi:10.1007/s00467-012-2184-y
6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
7. Hersh AO, Trupin L, Yazdany J, et al. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematodes. Arthritis Care Res. 2012;62 (8):1152-9.
8. Liu CC, Ahearn JM. The search for lupus biomarkers. Best Pract Res Clin Rheumatol. 2009;23:507-23.
9. Liang MH, Socher SA, Larson MG, et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythemotodes. Arthritis Rheum. 1989;32(9):1107- 18.
10. Faurschou M, Starklint H, Halberg P, et al. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006;33(8):1563- 9.
11. Chun HY, Chung JW, Kim HA, et al. Cytokine IL6 and IL10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007;27:461-6.
12. Illei GG, Tackey E, Lapteva L, et al. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum. 2004;50(6):1709-20.
13. Rahman A, Isenberg DA. Systemic lupus erythematodes. N Engl J Med. 2008;358(9):929-39.
14. Ching KH, Burbelo PD, Tipton C, et al. Two major autoantibody clusters in systemic lupus erythematosus. Plosone. 2012;7 (2):1-11.
15. Jurencak R, Fritzler M, Tyrrell P, et al. Autoantibodies in pediatric systemic lupus erythematosus: ethic grouping, cluster analysis, and clinical correlations. J Rheumatol. 2009;36:416-21.
16. Simon JA, Cabiedes J, Ortiz E, et al. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology. 2004;43:220-4.
17. Malleson PN, Sailer M, Mackinnon MJ. Usefulness of antinuclear antibody testing to screen for rheumatic disease. Arch Dis Child. 1997;77:299-304.
18. McGhee JL, Kickingbird LM, Jarvis JN. Clinical utility of antinuclear antibody tests in children. BMC Pediatr. 2004;4:13.
19. Jesus AA, Silva CA, Carneiro-Sampaio M, et al. Anti-C1q antibodies in juvenile-onset systemic lupus erythematodes. Ann N Y Acad Sci. 2009;1173:235-8.
20. Mok CC. Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol. 2010;638413:1-13.
21. Liu CC, Manzi S, Kao AH, et al. Cell-bound complement biomarkers for SLE: from benchtop to bedside. Rheum Dis Clin North Am. 2010;36(1):161-72.
22. Porcel JM, Ordo J, Castro-Salomo A, et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol Immunopathol. 1995;74:2883-8.
23. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematodes. Medicine (Baltimore). 2006;85 (3):147-56.
24. Welch TR, Blystone LW. Renal disease associated with inherited disorders of the complement system. Pediatr Nephrol. 2009;24 (8):149-1444.
25. Manzi S, Navratil JS, Ruffing MJ. Measurements of erythrocyte C4d and complement receptor 1 in the diagnosis of systemic lupus erythematodes. Arthritis Rheum. 2004;50 (11):3596-604.
26. Navratil JS, Manzi S, Kao AH. Platlet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum. 2006;54(2):670- 4.
27. Liu CC, Kao AH, Hawkins DM, et al. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Clin Transl Sci. 2009;2 (4):300-8.
28. Yang DH, Chang DM, Lai JH, et al. Usefulness of erythrocytebound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus. Rheumatology. 2009;48:1083- 7.
29. Arce E, Jacksan DG, Gill MA, et al. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic Lupus Erythematosus. J Immunol. 2001;167:2361-9.
30. Folzenlogen D, Hofer MF, Leung DY, et al. Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients. Clin Immunol Immunopathol. 1997;83:199-204.
31. Jacobi AM, Reiter K, Mackay M, et al. Activated Memory B Cell Subsets Correlate With Disease Activity in Systemic Lupus Erythematosus. Delineation by Expression of CD27, IgD, and CD95. Arthritis & Rheumatology 2008; 58(6):1762-1773
32. Bijl M, Horst G, Limburg PC, et al. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis. 2001;60:523-6.
33. Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166:6-10.
34. Villard JF, Bloch-Michel C, Neau-Cransac M, et al. HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus. Clin Exp Immunol. 2001;125:485-91.
35. Dai Z, Turtle CJ, Booth GC, et al. Normally occurring NKG2D+ CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile onset lupus. J Exp Med. 2009;206 (4):793-805.
36. Nath SK, Kilpatrick J, Harley JB. Genetics of human systemic lupus erythematodes: the emerging picture. Curr Opin Immunol. 2004;16(6):794-800.
37. Sestak AL, Nath SK, Sawalha AH. Current status of lupus genetics. Arthritis Res Ther. 2007;9(3):2010.
38. Yang Y, Chang EK, Zhou B. The intricate role of complement component C4 in human systemic lupus erythematodes. Curr Dir Autoimmun. 2004;7:98-113.
39. Al-Mayouf SM, Abanomi H, Eldali A. Impact of C1q deficiency on the severity and outcome of childhood systemic lupus erythematosus. Int J Rheum Dis. 2011;14(1):81-5.
40. Nikpour M, Dempsey AA, Urowitz MB, et al. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2008;67:1069- 75.
41. Kozyrev SV, Alarcon-Riquelme ME. The genetics and biology of Irf5-mediated signalling in lupus. Autoimmunity. 2007;40(8):591- 601.
42. Kyogoku C, Langefeld CD, Ortmann WA. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PtPn22 with human SLE. Am J Hum Genet. 2004;75(3):504- 7.
43. Firestein GS. Kelley's textbook of rheumatology. Philadelphia: Elsevier WB Saunders; 2008. p. 1270.
44. Marini R, Costallat LT. Young age at onset, renal involvement, and arterial hypertension are of adverse prognostic significance in juvenile systemic lupus erythematodes. Rev Rheum Engl Ed. 1999;6(6):303-9.
45. Zabaleta-Lanz ME, Munoz LE, Tapanes FJ, et al. Further description of early clinically silent lupus nephritis. Lupus. 2006;15 (12):845-51.
46. Mak A, Mok CC, Chu WP, et al. Renal damage in systemic lupus erythematodes: a comparative analysis of different age groups. Lupus. 2007;16(1):28-34.
47. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erithematous revisited. J Am Soc Nephrol. 2004;15:241-50.
48. Hiraki LT, Lu B, Alexander SR, et al. Endstage renal disease due to lupus nephritis among children in the US, 1995-2006. Arthritis Rheum. 2011;63(7):1988-97.
49. Watson L, Midgley A, Pilkington C, et al. Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus. Lupus. 2012;21:496-501.
50. Fine DM, Ziegenbein M, Petri M, et al. A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. Kidney Int. 2009;76(12):1284-8.
51. Ayodele OE, Okpechi IG, Swanepoel CR. Predictors of poor renal outcome in patients with biopsy-proven lupus nephritis. Nephrology. 2010;15(4):482-90.
52. Schwartz N, Michaelson JS, Putterman C. Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann N Y Acad Sci. 2007;1109:265-74.
53. Gwira JA, Wei F, Ishibe S, et al. Expression of neutrophil gelatinase-associated lipocalin regulates epithelial morphogenesis in vitro. J Biol Chem. 2005;280(9):7875-82.
54. Brunner HI, Mueller M, Rutherford C, et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2006;54(8):2577-84.
55. Hinze CH, Suzuki M, Klein-Gitelman M, et al. Neutrophil Gelatinase-associated Lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum. 2009;60:2772-81.
56. Brunner HI, Bennett MR, Mina R, et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheumatol. 2012;64 (8):2687-97.
57. Rovin BH, Birmingham DJ, Nagaraja HN, et al. Biomarker discovery in human SLE nephritis. Bulletin of the NYU Hospital of Joint Diseases. 2007;65(3):187-93.
58. Rubinstein T, Pitashny M, Levine B, et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology. 2010;49(5):960- 71.
59. Hinze CH, Suzuki M, Klein-Gitelman M, et al. Neutrophil Gelatinase-associated Lipocalin anticipates the Course of Global and Renal Childhood-Onset Systemic Lupus Erythematosus Disease Activity. Arthritis Rheum. 2009;60(9):2772-81.
60. Marks SD, Williams SJ, Tullus K, et al. Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in pediatric lupus nephritis. Nephrol Dial Transpl. 2008;23:3521-6.
61. Marks SD, Shah V, Pilkington C, et al. Urinary monocyte chemoattractant protein-1 correlates with disease activity in lupus nephritis. Pediatr Nephrol. 2012;25:2283-22889.
62. Hammad AM, Youssef HM, El-Arman MM. Transforming growth factor beta 1 in children with systemic lupus erythematosus: a possible relation with clinical presentation of lupus nephritis. Lupus. 2006;15:608-12.
63. Marks SD, Shah V, Pilkington C, et al. Renal tubular dysfunction in children with systemic lupus erythematosus. Pediatr Nephrol. 2005;20:141-8.
64. Suzuki M, Wiers K, Brooks EB, et al. Initial validation of a novel biomarker panel for active pediatric lupus nephritis. Pediatr Res. 2009;65:530-6.
65. Suzuki M, Ross GF, Wiers K, et al. Identification of urinary proteomics signature for lupus nephritis in children. Pediatr Nephrol. 2007;22:2047-57.
66. Chaussabel D, Quinn C, Shen J, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity. 2008;29(1):150-64.
67. Brunner HI, Huggins J, Klein-Gitelman MS. Pediatric SLE - towards a comprehensive management plan. Nat Rev Rheumatol. 2011;7(4):225-33.